Stipple Bio Secures $100 Million Series A to Advance Novel ADC Platform Targeting Tumor-Specific Epitopes
核心洞察
Stipple Bio (搜索) emerged from stealth with a heavily oversubscribed $100 million Series A financing co-led by RA Capital (搜索), a16z Bio+Health (搜索), and Nextech Invest (搜索) to advance precision oncology therapeutics.
The company's Pointillist Platform identifies tumor-specific cell surface epitopes to develop medicines with high therapeutic index, moving beyond conventional tumor-specific gene expression approaches.
Lead candidate STP-100 (搜索), a novel antibody drug conjugate designed to avoid on-target/off-tumor toxicity, is expected to enter clinical studies in early 2027.
Stipple Bio (搜索), a Cambridge-based biotechnology company, has closed a heavily oversubscribed $100 million Series A financing to advance its novel approach to precision oncology through epitope-level targeting. The financing was co-led by RA Capital (搜索), a16z Bio+Health (搜索), and Nextech Invest (搜索), with participation from existing investors including Emerson Collective Investments, GV (Google Ventures), LoLa Capital Partners, and GordonMD Global Investments.
The company emerged from stealth mode with its proprietary Pointillist Platform, which identifies tumor-specific cell surface epitopes to enable development of precision oncology medicines with high therapeutic index. This approach represents a departure from conventional methods that focus on tumor-specific gene expression.
Lead Candidate Targets On-Target/Off-Tumor Toxicity Challenge
Stipple Bio (搜索)'s lead candidate, STP-100 (搜索), is a novel antibody drug conjugate (ADC) incorporating tumor-specific binders designed to avoid on-target/off-tumor toxicity—a significant challenge in current ADC development. The compound is expected to enter clinical studies in early 2027.
"We are building upon deep cancer biology expertise to map, target and unlock tumor-specific epitopes which enable us to develop a pipeline of next-generation precision oncology therapeutics," said Jeff Landau, Chief Executive Officer of Stipple Bio (搜索). "This funding positions us to progress STP-100 (搜索) into the clinic and continue building a broad oncology pipeline."
Platform Technology Expands Druggable Target Space
The Pointillist Platform introduces an epitope-level approach to targeting tumor biology that has the potential to meaningfully expand the set of druggable oncology targets. According to Dr. Derek DiRocco, Partner at RA Capital (搜索) Management, "Lead candidate STP-100 (搜索) illustrates how this strategy can drive precise tumor targeting while sparing normal tissues—a key step toward improving therapeutic index in ADCs."
Dr. Vineeta Agarwala, General Partner at Andreessen Horowitz and lead investor for the a16z Bio+Health (搜索) Fund, emphasized the clinical significance of epitope-level specificity: "Clinical experience with prior antibody drugs has taught us that epitope-level specificity matters. Since the earliest days of Stipple Bio (搜索), we've been impressed by the team's vision to move beyond tumor-specific gene expression and to pioneer tumor-specific 'epitomics' in precision oncology."
Funding Strategy and Timeline
The proceeds from the Series A financing, which should fund the company into 2029, will be used to advance STP-100 (搜索) into multiple early-stage clinical studies and leverage the Pointillist Platform to identify additional tumor-specific cell surface epitopes for pipeline expansion.
In conjunction with the financing, Derek DiRocco, PhD and Thilo Schroeder, PhD joined the Stipple Bio (搜索) Board of Directors, which already includes Vineeta Agarwala MD, PhD, Owen Hughes, Jeff Landau, Aaron Ring MD, PhD, and Greg Verdine, PhD.
Scientific Foundation and Leadership
Stipple Bio (搜索) was founded in 2022 by cancer biology pioneers Dr. Aaron Ring, Associate Professor in the Translational Science and Therapeutics Division at Fred Hutch, and Dr. Aashish Manglik, Associate Professor of Pharmaceutical Chemistry at UCSF. Both founders believed that targeting tumor-specific cell surface epitopes could improve therapeutic index and unlock targets previously intractable with conventional oncology drug discovery methods.
The company's modality-agnostic platform approach positions it to develop a broad pipeline of precision cancer therapies based on epitope-level targeting, representing a potentially significant advancement in addressing the therapeutic index challenges that have limited the effectiveness of current targeted cancer treatments.